Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1461-1480 of 2,251 trials

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Venous Thromboembolism in Cancer: Abelacimab vs. Dalteparin

We are studying whether a new medication, abelacimab, can effectively prevent blood clots in patients with gastrointestinal or genitourinary cancer. This trial compares it to the standard treatment, dalteparin.

Venous Thromboembolism (VTE)6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Vibegron for Children with Neurogenic Detrusor Overactivity

We are studying the safety and effectiveness of vibegron in children aged 2 to under 18 with neurogenic detrusor overactivity who use clean intermittent catheterization. This trial aims to understand how well the medication works and how it is processed in young patients.

Neurogenic Bladder1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsUrology

Ovarian Stimulation: Follitropin Delta and Dydrogesterone

We are studying a new ovarian stimulation method for egg donors to see if it produces similar results to traditional approaches. This research may help improve fertility treatments in the future.

Healthy Oocyte Donors1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Acute Myeloid Leukemia: Midostaurin and Gemtuzumab Ozogamicin

We are studying a new combination treatment for patients with acute myeloid leukemia to see if it is safe and effective alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer: Genomics Guided Therapy Study

We are exploring whether a personalized treatment approach after surgery can improve outcomes for patients with early high-risk breast cancer. This study will assess survival rates and the safety of the new therapy.

Early Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Retinoblastoma: New Treatment Strategies

We are studying the effectiveness of a new chemotherapy method and other conservative treatments for children with retinoblastoma. Our goal is to see how well these treatments control the disease and support visual health.

Retinoblastoma Treatment>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Colorectal Cancer: New Treatment with 5-Fluorouracil, Panitumumab, and Sotorasib

We are studying a combination of medications for patients with advanced colorectal cancer who cannot receive standard chemotherapy. The goal is to see if this treatment helps control the disease and improves quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Triple Negative Breast Cancer: Atezolizumab, Vinorelbine, and Cyclophosphamide Study

We are studying a combination of three drugs to see if it can activate the immune system in patients with advanced triple negative breast cancer who have been treated with prior immunotherapy. The goal is to evaluate how well this treatment works and its safety.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Sepsis Treatment: Aminoglycoside Antibiotics and Isolation

We are studying the effects of combining aminoglycoside antibiotics with standard care and the role of protective isolation in critically ill neutropenic patients with sepsis. Our goal is to see how these strategies impact survival and other health outcomes.

Healthy Participants>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Lung Cancer Treatment: CT-P51 vs. Keytruda

We are comparing the effects and safety of CT-P51 and Keytruda in patients with untreated metastatic lung cancer. This study aims to find out if CT-P51 works as well as Keytruda when combined with chemotherapy.

Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Acute Myeloid Leukemia: Molidustat and Ivosidenib Combination

We are investigating whether the combination of molidustat and ivosidenib can effectively treat patients with IDH1-mutated acute myeloid leukemia or myelodysplastic syndrome. This study aims to assess how well this treatment works and its safety.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Colorectal Cancer: New Immunotherapy Treatment

We are studying a combination of Pembrolizumab and a Dendritic Cell Vaccine, followed by other medications, for patients with advanced colorectal cancer that hasn't responded to prior treatments. The goal is to see if this approach improves survival and safety.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Sacituzumab Govitecan with Bevacizumab for Brain Metastases in Lung Cancer

We are studying a combination of two medications for patients with brain metastases from non-small cell lung cancer. The goal is to see how well this treatment works in reducing tumor size and improving patient outcomes.

Lung Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncology

PD-1 Antibody for Metastatic Solid Tumors

We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.

Leptomeningeal Disease6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Tacrolimus and Blood Sugar Control in Dialysis Patients

We are studying how tacrolimus affects blood sugar levels in patients on hemodialysis waiting for a kidney transplant. This research may help improve diabetes management in these patients.

Hemodialysis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyNephrology

Chronic Lymphocytic Leukemia: Lisaftoclax and Acalabrutinib Study

We are testing a new drug combination for patients newly diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The study aims to see if this combination improves survival without disease progression compared to standard treatments.

Chronic Lymphocytic Leukemia (CLL) / Small Cell Lymphocytic Lymphoma (SLL)1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Melanoma: Regorafenib Treatment Study

We are studying the effects of regorafenib in patients with advanced melanoma who have already been treated. The goal is to see if it helps control the disease better when combined with other therapies.

Advanced Melanoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology

Extra-Mammary Paget's Disease: PAGETEX Device Study

We are studying the PAGETEX device to see if it helps control Extra-Mammary Paget's Disease of the vulva. The trial will also look at pain levels, quality of life, and patient satisfaction during treatment.

Paget's Disease of the Vulva6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Intracerebral Hemorrhage: Anticoagulation Strategies

We are studying whether avoiding anticoagulation or using a specific procedure helps improve health outcomes for patients after an intracerebral hemorrhage. We also aim to identify brain markers that may indicate future bleeding risks.

Cerebral Hemorrhage1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology